Metabolic deregulation is one ofthe frst tumor-specific alterations during cancer progression and is recognized as the seventh hallmark of cancer. Increased aerobic glycolysis provides cancer cells various sun/ival and growth advantages. The 14-3-3 proteins are involved in many important cellular processes. We discovered that 14-3-3^ is overexpressed in >40% of breast cancers. 14-3-3^ overexpression is significantly associated with increased disease recurrence and metastatic death of patients. In human breast cancer cells, overexpression of exogenous 14-3-3^ led to increased transformation, reduced apoptosis, whereas blocking 14-3-3^ expression by siRNA increased apoptosis and inhibited tumor growth. Excitingly, we recently found that 14-3-3^ overexpression in both MCFIOA mammary epithelial cells (MECs) and breast cancer cells led to increased glycolysis, whereas inhibiting 14-3-3^ expression decreased glycolysis. Moreover, 14-3-3^ conventional knockout mice had reduced uptake of 2-NBDG (a fluorescent derivative of D-glucose) in their livers and brains. Activation of HI F1 a is known as one ofthe principal mechanisms underlying metabolic reprogramming and 14-3-3^ overexpression also led to upregulation of HlF1a. Based on these, we hypothesize that 1) 14-3-3^ modulates mammary tumor progression/metastasis and 2) 14-3- 3t,-mediated metabolic deregulation may play a critical role in mammary tumor progression. To test the hypothesis, we will establish inducible, mammary gland-specific 14-3-3^ transgenic and knockout mouse models that allow us to explore in well-defined in vivo systems the complex roles of 14-3-3? in mammary tumorigenesis/metastasis and metabolic deregulation (Aims 1 &2). We will establish MECs and mammary tumor cell strains from 14-3-3? transgenic and knockout mice and use them to investigate whether 14-3-3?- mediated metabolic deregulation plays a role in transformation and tumor progression, determine the mechanisms of HIFia upregulation by 14-3-3? and its contribution to metabolic deregulation and transformation (Aim3). These comprehensive approaches will determine the functions of 14-3-3? in mammary gland development, transformation, tumor progression/metastasis, and the contribution of 14-3- 3?-mediated metabolic deregulation in these processes.
Currently, nothing is known on how 14-3-3? contributes to mammary gland development, transformation, tumorigenesis, metastasis and their relationship with metabolic alterations in vivo. This study will provide the initial answers to these important questions. Understanding the intrinsic link between 14-3-3?-mediated tumor progression/metastasis and cancer cell metabolic deregulation will also identify therapeutic targets for effective intervention and treatment ofthe highly aggressive, 14-3-3? overexpressing breast cancers.
|Yamaguchi, H; Du, Y; Nakai, K et al. (2018) EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 37:208-217|
|Joshi, Sonali; Yang, Jun; Wang, Qingfei et al. (2017) 14-3-3? loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. Am J Cancer Res 7:1654-1664|
|Hsu, Ming-Chuan; Hung, Wen-Chun; Yamaguchi, Hirohito et al. (2016) Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. Am J Cancer Res 6:628-38|
|Acharya, Sunil; Xu, Jia; Wang, Xiao et al. (2016) Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. Am J Cancer Res 6:981-95|
|Chen, Mei-Kuang; Hung, Mien-Chie (2016) Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. Am J Cancer Res 6:827-42|
|Boulay, Pierre-Luc; Mitchell, Louise; Turpin, Jason et al. (2016) Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. Cancer Res 76:2662-74|
|Mazumdar, Abhijit; Poage, Graham M; Shepherd, Jonathan et al. (2016) Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat 158:441-54|
|Haukaas, Tonje H; Euceda, Leslie R; Giskeødegård, Guro F et al. (2016) Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab 4:12|
|Lim, Seung-Oe; Li, Chia-Wei; Xia, Weiya et al. (2016) EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res 76:1284-96|
|Ko, How-Wen; Lee, Heng-Huan; Huo, Longfei et al. (2016) GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7:57131-57144|
Showing the most recent 10 out of 204 publications